Curogen Appoints Dr. Alexa Kimball and Dr. Jessica Allegretti to Scientific Advisory Board

Audio By Carbonatix

SEOUL, South Korea--(BUSINESS WIRE)--Sep 8, 2025--

Curogen Technology Co., Ltd., a South Korea-based biotechnology company focused on the global development of innovative treatments for autoimmune diseases, today announced the appointments of Alexa B. Kimball, MD, MPH and Jessica R. Allegretti, MD, MPH to its Scientific Advisory Board.

Dr. Alexa Kimball, MD, MPH is an internationally recognized expert in inflammatory skin diseases including Hidradenitis Suppurativa and Psoriasis. In addition to publishing more than 390 papers and conducting more than 150 clinical trials, Dr. Kimball has extensive experience in drug development and innovation, including two patents and several licensing agreements. Dr. Kimball is the recipient of numerous awards including American Skin Association Research Achievement Award in Inflammatory Skin Diseases, Fierce HealthCare's Women of Influence Award, and a Lifetime Achievement Award from the National Psoriasis Foundation.

Dr. Jessica Allegretti is the Medical Director of the Crohn’s and Colitis Center at Brigham and Women’s Hospital, where she developed and leads the hospital’s Fecal Microbiota Transplantation Program and is the lead investigator for multiple clinical trials. Dr. Jessica Allegretti is also an Associate Professor of Medicine at Harvard Medical School. She is the recipient of various awards including Sherman Prize, Emerging Leader in IBD 2020, Clinical Innovation Award Healio 2020 and Rising Healthcare Leader in IBD Crohn's and Colitis Foundation, New England Chapter 2015.

“We are thrilled to have Dr. Kimball and Dr. Allegretti join our Scientific Advisory Board,” said Chang-Woo Lee, Chief Executive Officer and Founder of Curogen. “Their extensive industry knowledge and leadership experience will provide valuable guidance and help accelerate our pipeline of small molecules and multi-specific biologics, reinforcing our commitment to provide meaningful solutions for patients with chronic autoimmune diseases.”

About Curogen Technology Co., Ltd.
Curogen is a biotechnology company headquartered in Seoul, South Korea, dedicated to the development of novel therapeutics for autoimmune diseases. Its pipeline includes innovative small molecules and multi-specific TRAP proteins targeting conditions such as inflammatory bowel disease, hidradenitis suppurativa, and other diseases with high unmet need.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250908126427/en/

CONTACT: Media Contact:

Jim Gold, Lumentus, +1-212-235-0251

KEYWORD: ASIA PACIFIC SOUTH KOREA

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS GENERAL HEALTH RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: Curogen Technology Co., Ltd.

Copyright Business Wire 2025.

PUB: 09/08/2025 08:00 AM/DISC: 09/08/2025 08:02 AM

http://www.businesswire.com/news/home/20250908126427/en